trending Market Intelligence /marketintelligence/en/news-insights/trending/mvdgpctharfl5gmsml90xa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Generex Biotechnology buying certain assets to push stock uplisting on Nasdaq

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Generex Biotechnology buying certain assets to push stock uplisting on Nasdaq

Generex Biotechnology Corp. said it completed the acquisition of the first tranche of certain assets from an undisclosed business involved in healthcare supplies.

In an Oct. 4 news release, the company said it will buy going-concern assets of a business providing certain specialty pharmacy services and products; surgical products and services, diagnostic testing for screening human blood, urine or saliva samples for the presence of narcotics, medications, alcohol and other drugs and substances; durable medical equipment services; ancillary healthcare services; and the provision of management services.

The Miramar, Fla.-based diagnostics company said the purchased assets generated more than $66 million in unaudited revenues in the past 12 months.

The acquisition will allow the company to qualify for up-listing its common stock to trade on the Nasdaq Capital Market.

Generex, which sells diagnostics for infectious diseases, is also planning to issue a 20-for-1 stock dividend with details to be disclosed later.

Brooks Houghton & Co. Inc. acted as Generex's M&A adviser, and Eckert Semans Cherin & Mellott LLC served as its counsel for the asset purchase.